Related by context. All words. (Click for frequent words.) 80 Drug Candidate 80 Kinase Inhibitor 79 Small Molecule 79 Prolongs Survival 78 Tumor Targeting 77 Receives Orphan Drug Designation 77 Recombinant Human 77 Presents Preclinical Data 76 Therapeutic Antibody 76 Epidermal Growth Factor Receptor 76 Systemic Delivery 76 RNAi Therapeutic 76 Anti Tumor 76 Present Preclinical Data 76 Initiates Clinical 76 Antitumor Activity 75 Phase 2b Clinical Trial 75 Demonstrates Potent 75 Novel Oral 75 Vitro Activity 75 Meets Primary Endpoint 75 Protease Inhibitor 75 Receptor Agonist 75 Phase 2b Trial 75 Tyrosine Kinase Inhibitor 75 Drug Resistant 75 Universal Flu Vaccine 75 Kinase Inhibitors 75 AnaSpec Introduces 75 Clinical Trial Results 75 Recombinant Protein 75 Phase 2a Clinical Trial 75 Single Dose 75 First Patient Dosed 74 Novel Therapeutic 74 Study Evaluating 74 Combination Therapy 74 Preclinical Data 74 Completes Patient Enrollment 74 Immune Responses 74 Develop Novel 74 Factor Receptor 74 Aptamer 74 Novel Mechanism 74 Receptor Antagonist 74 Prodrug 74 Mouse Model 74 Interferon Beta 74 Inflammatory Markers 74 Anti Tumor Activity 73 Novel Antibiotic 73 Seasonal Influenza Vaccine 73 Receives Milestone Payment 73 Tumor Necrosis Factor 73 Drug Shows Promise 73 Anticancer Agent 73 Files IND 73 Pivotal Study 73 Signaling Pathway 73 Investigational Compound 73 Phase IIb Trial 73 Transdermal Patch 73 Phase 2a Trial 73 Progenitor Cells 73 Initiates Clinical Trial 73 Collaborators Present 73 JAK Inhibitor 73 Inhibits 73 Cancer Cells 73 Aurora Kinase 73 Shows Promising 73 Complicated Skin 73 Previously Untreated 73 Phase III Clinical Trial 73 Antitumor 73 Respiratory Virus 73 Vaccine Adjuvant 73 Successfully Completes Phase 73 Therapeutic Vaccine 73 Vaccine Candidate 73 Patients Treated With 72 Influenza Virus 72 Phase IIb Clinical Trial 72 Phase IIa Clinical Trial 72 Endothelial Cells 72 Myelodysplastic Syndromes 72 Oral Fingolimod 72 Antibody Drug Conjugate 72 Tezampanel 72 Initiate Clinical Trial 72 Patent Covering 72 Cytochrome P# 72 Lung Cancer Drug 72 Antigen Specific 72 Previously Treated 72 Shows Promise Against 72 Antiviral Activity 72 Breast Cancer Cells 72 Dendritic Cells 72 Virus Infection 72 Monoclonal Antibodies 72 Submits NDA 72 Hsp# Inhibitor 72 Trial Evaluating 72 Smooth Muscle 72 Disease Progression 72 Polymerase Inhibitor 72 Initiates Phase II 72 Improves Survival 72 Antifungal 72 Investigational Treatment 72 Interferon Gamma 72 Lupus Drug 72 Epratuzumab 72 IND Application 72 Investigational Agent 72 Immunotherapeutic 72 Aliskiren 72 Osteoporosis Treatment 72 Rheumatoid Arthritis Drug 72 Mimetics 72 Nucleoside 72 Transcription Factor 72 Proteasome 72 Lymphoid 72 RNAi Therapeutics 72 Initiate Phase 72 Orally Active 72 Induces 72 Cytotoxicity 72 Combination Treatment 72 DNA Methylation 72 Phase III Trial 72 Immunomodulatory 72 HER2 Positive 72 Cytotoxic 71 Cancer Stem Cells 71 Monoclonal 71 Inflammatory Disease 71 Genotyping Test 71 Therapeutic Efficacy 71 Cancer Vaccines 71 Anthracycline 71 Oral Insulin 71 FDA Clears 71 Therapeutic Potential 71 Prostate Cancer Vaccine 71 Mouse Models 71 Pharmacokinetic Study 71 siRNA Delivery 71 Completes Enrollment 71 Chronic Hepatitis B 71 Cannabinoid 71 Humanized Anti 71 Improves Outcomes 71 Preclinical Study 71 humanized monoclonal 71 HDAC Inhibitor 71 Hepatitis B Virus 71 Fungal Infections 71 Patient Enrollment 71 Fast Track Status 71 Gene Mutation 71 Cell Proliferation 71 Advanced Renal Cell 71 Histone Deacetylase 71 Parathyroid Hormone 71 Assay Kits 71 Relapsed Refractory 71 Neuroprotection 71 Therapeutic Vaccines 71 Antiangiogenic 71 Cholesterol Lowering Drug 71 Anticancer Compound 71 Anticancer Drug 71 Synthetic Peptide 71 Shows Promise 71 Reports Preclinical Data 71 Hepatitis C Virus 71 Adjunctive Therapy 71 JAK2 Inhibitor 71 Replacement Therapy 71 Interferon Alpha 71 Rotavirus Vaccine 71 Anticancer Activity 71 Phase III Trials 71 Avian Flu Vaccine 71 Begin Clinical Trials 71 Advanced Melanoma 70 Dendritic Cell 70 Tumor Growth 70 Receptor Antagonists 70 Metastatic Melanoma 70 Initiates Phase 70 Protein Expression 70 protein tyrosine phosphatase 1B 70 Chemokine Receptor 70 Subunit 70 Immunomedics Announces 70 Oncolytic 70 Initiates Dosing 70 Sapacitabine 70 Inflammatory Diseases 70 Demonstrates Statistically Significant 70 Presents Positive 70 Demonstrates Significant 70 Hormone Refractory Prostate Cancer 70 Demonstrates Potential 70 FDA Approvals 70 Nucleic Acid 70 Xenograft 70 Holds Promise 70 Phase III Clinical Trials 70 Novel Protein 70 uricase 70 Antisense Drug 70 Disease Modifying 70 Patients Suffering 70 Prophylactic Treatment 70 Commences Phase 70 Anti Inflammatory 70 Oral Mucositis 70 Histone 70 Antibacterials 70 Human Monoclonal Antibody 70 Shown Effective 70 Plasmid DNA 70 Severe Sepsis 70 Leukemias 70 Nanoemulsion 70 Pooled Analysis 70 Nicotine Vaccine 70 Bosutinib 70 Attenuates 70 Antigens 70 Treatment Naïve 70 Autologous Stem Cell Transplantation 70 Renal Cell Carcinoma 70 Cutaneous T 70 Therapeutic Antibodies 70 Reductase 70 Demonstrates Efficacy 70 RNA Interference 70 Biomarker Study 70 Receives Approvable Letter 70 Exclusive License 70 Anti CD# Antibody 70 Atopic Dermatitis 70 Molecular Diagnostic Test 70 Bavituximab 70 Preclinical Models 70 Diabetic Nephropathy 70 Antiviral Drugs 70 Analogs 70 oral prodrug 70 Safinamide 70 Adjuvant Chemotherapy 70 Immune Cells 70 FDA Accepts 70 Chronic Hepatitis C 70 Milestone Payment 70 Estrogen Receptor 70 Autoimmune Disease 69 Commercialize 69 Romidepsin 69 Clinical Outcome 69 Receives Orphan Drug 69 Hormone Receptor Positive 69 Hepatocellular Carcinoma 69 Chronic Myeloid Leukemia 69 Blood Pressure Drug 69 Circulating Tumor Cells 69 Adjuvant Treatment 69 Pharmacokinetics PK 69 Peginterferon 69 Enzyme Replacement Therapy 69 Investigational Drug 69 FDA Okays 69 Tumor Suppressor 69 Pivotal Phase III 69 Mylan Receives Approval 69 Initiates Phase III 69 Malignant Melanoma 69 Skeletal Muscle 69 Beneficial Effects 69 Psoriasis Drug 69 Tyrosine Kinase 69 Advanced Pancreatic Cancer 69 Collaborators Publish 69 Advanced Prostate Cancer 69 Genes Involved 69 Molecular Diagnostic 69 Insulin Resistance 69 Potent Antiviral Activity 69 Proven Effective 69 Phase 1b Clinical Trial 69 Protein Kinase 69 Anti Angiogenesis 69 Proves Effective 69 Angiogenic 69 Phase 2b Study 69 Cell Adhesion 69 Test Detects 69 Study Demonstrates 69 Initiates Clinical Trials 69 Infected Patients 69 Protein Synthesis 69 Mg Usa 69 Autoimmune Diseases 69 Combination REOLYSIN R 69 Survival Benefit 69 PEGylated Fab fragment 69 Presents Preclinical 69 Commence Phase 69 Benign Prostatic Hyperplasia 69 Anthrax Toxin 69 Cyclin Dependent 69 Molecular Mechanism 69 Mucosal 69 Pulmonary Arterial Hypertension 69 Adjuvanted 69 Conjugate 69 Suppresses 69 Omacetaxine 69 Advanced Colorectal Cancer 69 Researchers Identify 69 Topical Treatment 69 Gene Silencing 69 Demonstrated Significant 69 CYT# potent vascular disrupting 69 Valopicitabine 69 Clinical Trial Evaluating 69 Gastric Cancer 69 See CLINICAL PHARMACOLOGY 69 Initiates Enrollment 69 Biosynthesis 69 PRN FDA Approves 69 Epilepsy Drug 69 Vaccine Adjuvants 69 Treated Patients 69 Ozarelix 69 Dehydrogenase 69 Metastatic Colorectal Cancer 69 Modulates 69 Adenoviral 69 Relapsing Multiple Sclerosis 69 Oligonucleotide 69 Pivotal Phase 69 Phospholipase A2 69 Azacitidine 69 Oral Formulation 69 Hepatitis B Vaccine 69 Human Monoclonal Antibodies 69 Nitazoxanide 69 Therapeutic Targets 69 Efficacy Trial 69 Respiratory Syncytial Virus RSV 69 Prodrugs 69 Protein Biomarker 69 Cancer Vaccine 68 Novel Vaccine 68 BiTE Antibody 68 Chemotherapeutic Agents 68 Soft Tissue Sarcoma 68 Induces Apoptosis 68 Metabolic Disease 68 Hypercholesterolemia 68 targeting CD# 68 Metabolites 68 Transfection 68 Epitopes 68 Effectively Treats 68 Granulocyte Colony Stimulating Factor 68 Gout Drug 68 Anti Angiogenic 68 Lupus Nephritis 68 Protein Interactions 68 Angiotensin Converting Enzyme 68 Targeted Therapy 68 Pandemic Influenza Vaccine 68 Significantly Improves 68 Innate Immune 68 pan HDAC inhibitor 68 Protein Linked 68 Cardiomyocytes 68 Diagnostic Tests 68 Progenitor Cell 68 Blinatumomab 68 Liposomal 68 Maribavir 68 Is Well Tolerated 68 Presents Positive Preclinical 68 Statistically Significant 68 Pafuramidine 68 Transgenic Mice 68 CD# CEA 68 Phase Ib Clinical Trial 68 Anti Inflammatory Drug 68 TB Vaccine 68 Epithelial 68 Immunogenicity 68 Patents Covering 68 Improve Survival 68 Pegylated 68 Ligands 68 Malaria Vaccine 68 II Clinical Trial 68 Treatment Shows Promise 68 Inhibits Growth 68 Intravenous Human 68 Subtypes 68 pralatrexate injection folate analogue 68 Vicriviroc 68 Bazedoxifene 68 Granted Orphan Drug 68 Successfully Treated 68 Shows Statistically Significant 68 Tumor Cells 68 Long Term Efficacy 68 Taxane 68 PKC# 68 Iloperidone 68 agonistic human 68 Begins Dosing 68 Significantly Improved 68 Allogeneic 68 Cethromycin 68 Ebola Vaccine 68 Oral Spray 68 Antibody Discovery 68 Confirms Efficacy 68 Generic Version 68 Unresectable 68 Treatment Reduces 68 platform HDL Mimetic 68 Chronic Lymphocytic Leukemia 68 Somatostatin 68 Mutational 68 Antisense Oligonucleotides 68 Magnetic Nanoparticles 68 Doripenem 68 Well Tolerated 68 Patients Receiving 68 Commonly Used 68 von Willebrand Factor 68 Inhaled Corticosteroids 68 Adjuvant Therapy 68 Genotypes 68 Personalized Immunotherapy 68 Calcitonin 68 IND Filing 68 Transdermal Delivery 68 Vaccine Shows Promise 68 Treatment Experienced 68 Immune Cell 68 Potent Anti 68 Receives FDA Clearance 68 Stakeholder Opinions 68 rxRNA 68 Fixed Dose 68 Macrolide 68 Breast Cancer Recurrence 68 TNF Alpha 68 Avian Influenza Vaccine 68 Novel Peptide 68 Immunogenic 68 Dasatinib 68 NDA Submission 68 Decitabine 68 TNF Blockers 68 Lanthanum Carbonate 68 NS#/#A protease 68 Gastrointestinal Stromal Tumors 68 Ofatumumab 68 Low Dose 68 Cancer Therapies 68 Sustained Release 68 Mg Uk 68 Ridaforolimus 68 Pralatrexate 68 Cell Lymphoma 68 Protein Involved 68 Develops Novel 68 Invasive Fungal Infections 68 Anticancer Agents 68 Metastatic Prostate Cancer 68 Diabetic Neuropathy 68 candidates Azedra 68 Receives Positive Opinion 68 Novel Inhibitor 68 anionic backbone 68 TKB# 68 Myelodysplastic Syndrome MDS 68 Secretion 68 ALN HPN 68 Tigecycline 68 Sevelamer 68 Treatment Resistant 68 Crit Rev 68 Lung Cancer Trial 68 Expanded Indication 68 Signaling Pathways 68 Glycoprotein 68 Novel Therapies 68 Glatiramer Acetate 68 Fibrinogen 68 Janus kinase 68 Commercialize Novel 68 Study Showed 68 Neural Stem Cells 68 Quantitation 68 Conjugated 68 MEK inhibitor 68 Oral Calcitonin 67 Hematological Malignancies 67 Companion Diagnostic 67 Antiviral Therapy 67 Pertuzumab 67 matrix metalloproteases 67 anti CD3 67 Hepatocellular 67 Antimicrobial Activity 67 AEG# 67 Dose Ranging Study 67 Influenza Vaccine 67 Contrast Agents 67 Protease Inhibitors 67 Dose Escalation 67 Nilotinib 67 Shows Efficacy 67 Elagolix 67 Inactivated 67 Antithrombin 67 Monotherapy 67 Rheumatoid Arthritis Patients 67 Licenses Novel 67 Randomized Phase 67 MEK Inhibitor 67 Viral Suppression 67 Smallpox Vaccine 67 Breast Tumors 67 targeted radiotherapeutic 67 histone deacetylase HDAC inhibitor 67 Dose Escalation Study 67 Lentiviral 67 Potent Inhibitor 67 Endovascular Treatment 67 Multiple Myeloma Patients 67 Squamous 67 orally administered inhibitor 67 Cardiac Function 67 Brain Cells 67 HER1 67 Asthma Treatment 67 Elderly Patients 67 Inhibitor 67 Improved Survival 67 Gamma secretase 67 Efficacious 67 Lowers Risk 67 chimeric monoclonal antibody 67 Palifosfamide 67 Lung Cancer Survival 67 Newly Diagnosed Multiple Myeloma 67 Glycosylation 67 Demonstrates Ability 67 Hypertensive Patients 67 receptor tyrosine kinase inhibitor 67 KSP inhibitor 67 telomerase therapeutic 67 Refractory Hodgkin Lymphoma 67 Hospital Acquired Pneumonia 67 Regenerative Cells 67 Initiates Phase 2b 67 non nucleoside inhibitor 67 Placebo Controlled Trial 67 DNA intercalator 67 Novel Method 67 Tyrosine Kinase Inhibitors 67 Prodarsan R 67 humanized anti 67 Inflammatory Arthritis 67 TRAIL R2 67 Generic Versions 67 Gene Expression Analysis 67 Fibroblast 67 FOLOTYN ® 67 Renal Cell Cancer 67 Patients Treated 67 Allergic Rhinitis 67 Genetic Variation 67 Viral Infections 67 Demonstrates Positive 67 Cell Transplants 67 Novel Anticancer 67 NMDA Receptor 67 Bone Metastases 67 HIV Integrase 67 Treatment Regimen 67 Fluticasone 67 Vaccine Protects Against 67 Pivotal Trials 67 Peginterferon Alfa 2a 67 Hepatocytes 67 Experimental Vaccine 67 Genes Linked 67 KL4 Surfactant 67 Achieves Primary Endpoint 67 Ion Channels 67 Diabetic Patients 67 Cell Differentiation 67 Leukemia Cells 67 Elotuzumab 67 Arthritis Drug 67 Macrophage 67 cMET 67 Plus Ribavirin 67 receptor modulators 67 Integrase Inhibitor 67 Anticoagulant 67 Gene Linked 67 CYP#A# CYP#D# 67 Neoadjuvant Chemotherapy 67 Oral Interferon 67 Disease IBD 67 Dengue Virus 67 Novel Anti Inflammatory 67 Hepatitis C Infection 67 Breast Cancer Metastasis 67 Faropenem 67 investigational humanized monoclonal antibody 67 Mesenchymal Stem Cells 67 Naive Patients 67 Scientists Identify 67 ARRY # 67 Dapagliflozin 67 MicroRNA 67 Diabetic Foot Ulcer 67 FDA Approves 67 Treating Chronic 67 SPRYCEL ® 67 Blood Clotting 67 Metastatic Renal Cell Carcinoma 67 Secondary Hyperparathyroidism 67 HCV Protease Inhibitor 67 Preclinical Efficacy 67 Therapeutic Competitors Companies 67 Melphalan 67 Intravenous Formulation 67 Confirmatory Phase 67 Integrase 67 Janus Kinase 67 Epitope 67 Tuberculosis Vaccine 67 MKC# MT 67 Multipotent 67 Telaprevir VX 66 HDAC enzymes 66 Locked Nucleic Acid LNA 66 Transmembrane 66 sodium glucose cotransporter 66 selective kinase inhibitor 66 Phenotypes 66 Systemic Sclerosis 66 ALN TTR 66 Migraine Drug 66 Cardiotoxicity 66 Targeted Therapies 66 Chronic Myelogenous Leukemia 66 Glucocorticoid 66 Secretase 66 antibody MAb 66 Announces FDA Clearance 66 Tesetaxel 66 FDA APPROVES 66 Inactivation 66 Nicotinic 66 Apoptotic 66 Meta Analysis 66 Cerebrospinal Fluid 66 Chemoradiation 66 Gene Variant 66 Announces Initiation 66 Treatment Naïve Patients 66 Preclinical Evaluation 66 Slow Progression 66 Transcriptional 66 Interferon gamma 66 AAG geldanamycin analog 66 Gets FDA Clearance 66 Earns Milestone Payment 66 immunotoxin 66 Fondaparinux 66 Files Investigational 66 Renal Cancer 66 Solid Tumors 66 Randomized Double Blind 66 Uric Acid 66 Hepatitis C Virus HCV 66 iobenguane 66 monoclonal antibody conjugated 66 Carboplatin Paclitaxel 66 Oritavancin 66 Drug Formulation 66 Vascular Inflammation 66 Thiovir 66 Cancer Treatments 66 Reduces Risk 66 PDE# 66 Medoxomil 66 Medullary Thyroid Cancer 66 Advanced Ovarian Cancer 66 Patient Enrolment 66 Myeloma Patients 66 Drug Prevents 66 Muscarinic 66 Alfacell proprietary ribonuclease 66 Darinaparsin 66 ceftazidime 66 Inhalation Aerosol 66 Proteases 66 Prostate Tumors 66 Neural Stem Cell 66 Immune Mediated 66 Placebo Controlled Study 66 VentiRx Pharmaceuticals 66 familial amyloidotic polyneuropathy FAP 66 highly selective inhibitor 66 Kidney Function 66 Allosteric 66 accumulate preferentially 66 Selective Inhibitor 66 Interferon alpha 66 Desvenlafaxine Succinate 66 Novel Treatments 66 Submits IND 66 Fulvestrant 66 Tumor Targeted 66 flavopiridol 66 Radiation Induced 66 Novel Small Molecule 66 Angiotensin 66 SAR# [002] 66 mertansine 66 Teva Provides Update 66 selective phosphodiesterase 66 PEGylated anti 66 Mutation Detection 66 Unfractionated Heparin 66 Polymorphisms 66 Immunosuppressant 66 Entry Inhibitor 66 Newly Diagnosed 66 Nasal Powder 66 Could Detect 66 Genes Identified 66 Pivotal Trial 66 Gene Expression Profiling 66 recombinant subunit vaccine 66 Drug Fails 66 Intranasal 66 TNF Tumor Necrosis Factor 66 Fabry Disease 66 Stem Cell Transplants 66 Chronic Inflammation 66 polymerase inhibitor 66 Mutagenesis 66 Phosphatase 66 IAP inhibitor 66 Colorectal Adenomas 66 Levoleucovorin 66 Piperacillin 66 Investigational Oral 66 Interferon beta 1a 66 Non Responders 66 Controlled Study 66 Files Patent Application 66 Transcriptome 66 Prostate Cancer Patients 66 Asthma COPD 66 Predict Risk 66 Valproic Acid 66 Multicenter Randomized 66 Retinoic Acid 66 Autoimmune Disorders 66 Oral Cavity 66 Cholesterol Lowering 66 Tumor Suppressor Gene 66 Skin Cells 66 First Patient Enrolled 66 Controlled Clinical Trial 66 Lung Cancers 66 Cyclooxygenase 2 66 oncolytic virus therapies 66 Highly Potent 66 Effective Treatments 66 soluble tumor necrosis 66 IAP inhibitors 66 Diffuse Large B 66 Interferon Alfa 66 Sustained Efficacy 66 MKC# MKC# PP 66 Treatment Naive Patients 66 Voreloxin 66 Phase III Pivotal 66 Beta Blocker 66 Therapeutic Effects 66 Protein Kinase C 66 Severe Asthma 66 Blood Vessels 66 Retroviral 66 Dose Response 66 Oxidative Stress 66 Slows Progression 66 Glufosfamide 66 Drug Combo 66 Inhalation Solution 66 Controlled Trial 66 Pediatric Patients 66 Gastrointestinal Disorders 66 OMP #M# 66 Antibiotic Resistant 66 Cytotoxic T 66 Cellular Immunotherapy 66 Atypical Hemolytic Uremic Syndrome 66 Adefovir 66 Data Suggest 66 Tipranavir 66 ABLYNX 66 proprietary Locked Nucleic 66 P#Y# [001] 66 virus AAV 66 Multidrug Resistance 66 Pathogen Detection 66 Inhibitory 66 Bevacizumab 66 EZN 66 Antibody 66 Monoclonal antibody 66 proteasome inhibitor 66 Bortezomib 66 Insulin Glargine 66 Receives Fast Track 66 pathophysiological effects 66 Postdoctoral Position 66 Cytomegalovirus CMV 66 Viral Infection 65 RAV# 65 Relapsing Remitting Multiple Sclerosis 65 Trastuzumab DM1 65 Bacterial Cell 65 Virus Linked 65 Novel Antibody 65 Chimeric 65 Immunotherapies 65 Clinical Study Shows 65 histone deacetylase inhibitor 65 Epstein Barr Virus EBV 65 Novel Compound 65 Gene Variants 65 Eukaryotic 65 Gleevec resistant 65 Appears Safe 65 Serious Infections 65 Oligonucleotides 65 antisense inhibitor 65 hypoxia inducible factor 65 Monocytes 65 Genetic Mutation 65 Hematological Cancers 65 Antisense 65 Hepatitis C Genotype 65 Identifies Potential 65 Pegylated Interferon 65 Mycophenolate Mofetil 65 Peripheral Blood 65 FLT3 65 Neutralizing Antibodies 65 poly ADP ribose polymerase 65 Detect Cancer 65 Overactive Bladder 65 Protease 65 XL# XL# 65 Osteoporosis Drug 65 selective agonist 65 Preclinical Testing 65 Malignant Glioma 65 Receptor Signaling 65 antisense inhibition 65 Pathway Inhibitor 65 product platforms AZX# 65 Antidepressant Drug 65 Nuclear Receptors 65 Integrin 65 monoclonal anti 65 mGluR5 negative 65 Prospective Randomized 65 CCX# 65 Vaginal Gel 65 Nebulized 65 Mol Cell 65 Human Neural Stem 65 Plaque Psoriasis 65 Autoantibodies 65 JVRS 65 Therapeutic Competitors Report 65 Neurogenesis 65 ara C 65 Immune Therapy 65 Diabetic Neuropathic Pain 65 Viral Load 65 Nymox NX 65 Prove Effective 65 FDA Clearance 65 Remission Maintenance 65 Genetic Tests 65 Endoplasmic Reticulum 65 vivo validation 65 Wound Dressing 65 Postmenopausal Women 65 Cholinesterase Inhibitors 65 Hormone Receptor 65 Emerging Therapies 65 Reduces Pain 65 Innate Immunity 65 Therapy Improves 65 Fracture Risk 65 Tablet Formulation 65 Dosage Forms 65 Helps Predict 65 NICE Recommends 65 Potentially Fatal 65 multikinase inhibitor 65 Postmenopausal Osteoporosis 65 Clofarabine 65 Hepatitis C Patients 65 interleukin IL -# 65 Brain Metastases 65 Thiarabine 65 Inhibitors 65 Vascular Disrupting Agent 65 Sym# 65 Capecitabine 65 Atypical Antipsychotic 65 Hepatocyte 65 Parainfluenza 65 Liver Injury 65 Olaparib 65 Antigenics QS 65 Bronchodilator 65 Tocilizumab 65 Stem Cell Treatment 65 Acute Ischemic Stroke 65 tumor xenograft models 65 Transdermal Drug 65 Completes Dosing 65 Assay Kit 65 Therapy Shows Promise 65 Orally administered 65 Cocaine Addiction 65 Randomized Double blind 65 IgG1 65 Pandemic Flu Vaccine 65 PNP inhibitor 65 Analytical Tool 65 Therapeutic Monoclonal Antibodies 65 Newly Identified 65 Prostate Cancer Cells 65 novel histone deacetylase 65 GW# [003] 65 Influenza Vaccine Production 65 Luteinizing Hormone Releasing Hormone 65 Mimetic 65 Genetic Disorder 65 Chemotherapeutic 65 Upregulation 65 Scientists Uncover 65 Clinical Study 65 Hematopoietic 65 Myolimus 65 Lymphocytic 65 Irinotecan 65 Haemophilus b Conjugate 65 Preclinical Studies 65 CDDO Im 65 Electroporation 65 peptibody 65 Tumor Response 65 Anti Phospholipid Therapy 65 Multimeric 65 Platelet Derived Growth 65 PARI Pharma GmbH 65 Chronic Lymphocytic Leukemia CLL 65 Multidrug Resistant 65 PROSTASCINT R 65 Epothilone 65 T Lymphocyte 65 Novel Compounds 65 Pharmaceuticals Initiates